Skip to main content
. Author manuscript; available in PMC: 2017 Nov 14.
Published in final edited form as: Cancer. 2015 May 18;121(17):2942–2950. doi: 10.1002/cncr.29421

Figure 4.

Figure 4

IL15 levels (A) and CD33+DLA-DR- (MDSCs) cell number (B) in patients’ plasma samples for baseline (7 days before enrollment) and during mushroom treatment (week 13). CR: Complete response (n=2), PR: Partial response (n=1 for (A), n=2 for (B)), NR: Non response (n=9). PBMCs: Peripheral blood mononuclear cells. *P < 0.05, Wilcoxon rank sum test.